RNAZ vs. PCSA, IBIO, SHPH, TENX, PULM, CANF, KTTA, UPC, ASLN, and AIMD
Should you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Processa Pharmaceuticals (PCSA), iBio (IBIO), Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Pulmatrix (PULM), Can-Fite BioPharma (CANF), Pasithea Therapeutics (KTTA), Universe Pharmaceuticals (UPC), ASLAN Pharmaceuticals (ASLN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Processa Pharmaceuticals (NASDAQ:PCSA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Processa Pharmaceuticals and Processa Pharmaceuticals both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 0.63 beat Processa Pharmaceuticals' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media.
TransCode Therapeutics' return on equity of -141.42% beat Processa Pharmaceuticals' return on equity.
Processa Pharmaceuticals received 3 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 85.71% of users gave TransCode Therapeutics an outperform vote while only 47.37% of users gave Processa Pharmaceuticals an outperform vote.
Processa Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500.
Processa Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 222.58%. TransCode Therapeutics has a consensus target price of $480.00, suggesting a potential upside of 41,279.31%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe TransCode Therapeutics is more favorable than Processa Pharmaceuticals.
91.9% of Processa Pharmaceuticals shares are held by institutional investors. 22.2% of Processa Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Processa Pharmaceuticals beats TransCode Therapeutics on 10 of the 14 factors compared between the two stocks.
Get TransCode Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransCode Therapeutics Competitors List
Related Companies and Tools
